



Source details

Pregnancy Hypertension

Scopus coverage years: from 2010 to Present

Publisher: Elsevier

ISSN: 2210-7789 E-ISSN: 2210-7797

Subject area: Medicine: Obstetrics and Gynecology Medicine: Internal Medicine

Source type: Journal

CiteScore 2022

4.2



SJR 2022

0.868



SNIP 2022

0.892



[View all documents >](#)

[Set document alert](#)

[Save to source list](#) [Source Homepage](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022

$$4.2 = \frac{2,034 \text{ Citations 2019 - 2022}}{482 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$4.4 = \frac{1,689 \text{ Citations to date}}{380 \text{ Documents to date}}$$

Last updated on 05 October, 2023 • Updated monthly

CiteScore rank 2022

Category	Rank	Percentile
Medicine		
└ Obstetrics and Gynecology	#59/197	70th
Medicine		
└ Internal Medicine	#63/140	55th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

All content on this site: Copyright © 2023 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.



SJR
Scimago

SJR
Scimago Journal & Country Rank

[Home](#) | [Journal Rankings](#) | [Country Rankings](#) | [Viz Tools](#) | [Help](#) | [About Us](#)

Pregnancy Hypertension

<p>COUNTRY</p> <p>Netherlands</p> <div style="background-color: #333; color: white; padding: 2px; margin-top: 5px;"> </div> <div style="background-color: #333; color: white; padding: 2px; margin-top: 5px;"> </div>	<p>SUBJECT AREA AND CATEGORY</p> <p>Medicine</p> <ul style="list-style-type: none"> Internal Medicine Obstetrics and Gynecology 	<p>PUBLISHER</p> <p>Elsevier BV</p>	<p>H-INDEX</p> <p style="font-size: 2em; font-weight: bold;">34</p>
<p>PUBLICATION TYPE</p> <p>Journals</p>	<p>ISSN</p> <p>22107797, 22107789</p>	<p>COVERAGE</p> <p>2010-2022</p>	<p>INFORMATION</p> <p>Homepage</p> <p>How to publish in this journal</p> <p>m.m.faas@umcg.nl</p>

SCOPE









Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health aims to stimulate research in the field of hypertension in pregnancy, disseminate the useful results of such research, and advance education in the field. We publish articles pertaining to human and animal blood pressure during gestation, hypertension during gestation including physiology of circulatory control, pathophysiology, methodology, therapy or any other material relevant to the relationship between elevated blood pressure and pregnancy. The subtitle reflects the wider aspects of studying hypertension in pregnancy thus we also publish articles on in utero programming, nutrition, long term effects of hypertension in pregnancy on cardiovascular health and other research that helps our understanding of the etiology or consequences of hypertension in pregnancy. Case reports are not published unless of exceptional/outstanding importance to the field.

Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS options

1 Hypertension in Pregnancy USA	2 Journal of Maternal-Fetal and Neonatal Medicine GBR	3 Journal of Pregnancy USA	4 South African Journal of Obstetrics and Gynaecology ZAF	5 BJOG: An International Journal of Obstetrics and Gynaecology GBR
--	--	---	--	---



Pregnancy Hypertension ← Show this widget in your own website

Obstetrics and Gynecology
best quartile

SJR 2022
0.87

powered by scimagojr.com

Just copy the code below and paste within your html code:
``

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.

Metrics based on Scopus® data as of April 2023



Loading comments...

Developed by: Powered by:

Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2022. Data Source: Scopus®


EST MODUS IN REBUS
Horatio (Satire 1.1.106)

Cookie settings





Volume 33 September 2023 ISSN 2210-7



PREGNANCY HYPERTENSION

An International Journal of Women's Cardiovascular Health



Pregnancy Hypertension

Supports open access

Submit your article ↗

Menu

Search in this journal

Volume 32

Pages 1-70 (June 2023)

Download full issue

Previous vol/issue

Next vol/issue

Receive an update when the latest issues in this journal are published

Sign in to set up alerts

Full text access

Editorial Board

Page ii

View PDF

Full Length Articles

FEEDBACK

Pregnancy Hypertension

Supports open access

Submit your article ↗

Menu



Article preview ▾

Research article Abstract only

Rural-urban residence and sequelae of hypertensive disorders of pregnancy in the first year postpartum, 2007 – 2019

Mariah Pfeiffer, Catherine Gelsing, Kristin Palmsten, Heather S. Lipkind, ... Katherine A. Ahrens
Pages 10-17

Article preview ▾

Research article Abstract only

Clinical characteristics and subsequent need for anti-hypertensive agents in the postpartum period for hypertensive disorders of pregnancy

Gianna L. Wilkie, Colleen M. Harrington
Pages 18-21

Article preview ▾

Research article Abstract only

Comparison of Zuspan regimen and its 12-hour modification in women with severe pre-eclampsia and eclampsia in two hospitals in Abeokuta

Elizabeth Oluwakemi Grillo, David Olalekan Awonuga, Iyabo Olabisi Florence Dedeke, Olusanya Abiodun, ... Chimaobi Nwankpa
Pages 22-27

Article preview ▾

Research article Abstract only

FEEDBACK

Pregnancy Hypertension

Supports *open access*

Submit your article ↗

Menu



Research article Open access

WILL (When to induce labour to limit risk in pregnancy hypertension): Protocol for a multicentre randomised trial

Katie Kirkham, Sue Tohill, Jennifer A. Hutcheon, Jon Dorling, ... Laura A. Magee

Pages 35-42



[View PDF](#)

Article preview

Research article Abstract only

Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue

Hannah Blakey, Ruyue Sun, Long Xie, Rebecca Russell, ... Graham Lipkin

Pages 43-49

Article preview

Research article Abstract only

RUPP Th17s cause hypertension and mitochondrial dysfunction in the kidney and placenta during pregnancy

Sarah Fitzgerald, Evangeline Deer, James Hogg, Denise C. Cornelius, ... Babbette LaMarca

Pages 50-56

Article preview

Research article Abstract only

FEEDBACK

Pregnancy Hypertension

Supports open access

Submit your article ↗

Menu



Article preview

Abstract

Abstract

Objectives

To evaluate maternal hypertension, risk of cardiovascular disease (CVD), and metabolic syndrome five years after delivery in preterm preeclampsia (P-PE), term preeclampsia (T-PE), and normal pregnancy.

Study design

This was a retrospective cohort study of women who delivered at Dr. Soetomo Academic Hospital (Indonesia) in 2013 with a diagnosis of PE and were compared with women with

Research article Abstract only

Prediction of adverse neonatal outcome at admission for early-onset preeclampsia with severe features

Anna Peguero, Lorena Fernandez-Blanco, Edurne Mazarico, Leticia Benitez, ... Francesc Figueras
Pages 64-69

Article preview

Short Communications

Short communication Abstract only

FEEDBACK

Pregnancy Hypertension

Supports open access

Submit your article ↗

Menu



ELSEVIER

All content on this site: Copyright © 2023 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.



FEEDBACK



ScienceDirect®

Pregnancy Hypertension

Supports *open access*

4.2

CiteScore

2.2

Impact Factor

[Submit your article ↗](#)

[Guide for authors](#)

☰ Menu

🔍 Search in this journal

➤ [Aims and scope](#)

➤ [Editorial board](#)

➤ [Announcements](#)

Editorial board by country/region

29 editors and editorial board members in 15 countries/regions

1 Australia (6)

2 United States of America (5)

3 Netherlands (3)

➤ [See more editors by country/region](#)

Editorial board

Editors-in-Chief

Professor Annemarie Hennessy

Western Sydney University, Penrith, New South Wales, Australia

Dr. S. Ananth Karumanchi, MD

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America

Associate Editors

Dr. Marijke Faas

University of Groningen, Faculty of Medical Sciences, Groningen, Netherlands

Professor Anne Cathrine Staff, MD, PhD

Oslo University Hospital, Oslo, Norway

Editorial Board

Dr. Dilly Anumba

Dr. Mark Brown, MB BS FRACP MD

Saint George Hospital, Kogarah, New South Wales, Australia

pregnancy hypertension; kidney supportive care, pregnancy hypertension, kidney supportive care

Dr. Ana Sofia Cerdeira



Professor Catherine Cluver, MBChB, FCOG, MMed, Cert MFM, PhD

Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa

Preeclampsia

Dr. Gus Dekker

The University of Adelaide, Adelaide, Australia

Dr. Tom Easterling

University of Washington, Seattle, Washington, United States of America

Dr. Marcus Escudero

Dr. Joey P. Granger

Dr. Leandro Gustavo de Oliveira

National Council for Scientific and Technological Development (CNPq), Lago Sul, Brazil



Assoc. Professor Amanda Henry, PhD

University of New South Wales, Sydney, New South Wales, Australia

preeclampsia, pregnancy hypertension, cardiovascular disease prevention, health promotion, pregnancy complications, women's health, medical education, obstetric ultrasound, clinical trials, postpartum care, pregnancy microbiome

Dr. Carlo Hubel

University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Professor Jon Hyett, MBBS BSc MD MRCOG FRANZCOG

Western Sydney University - Campbelltown Campus, Campbelltown, Australia

prediction and prevention of preeclampsia

Assoc. Professor Tu'uhevaha Kaitu'u-Lino

The University of Melbourne, Department of Obstetrics and Gynaecology, Parkville, Victoria, Australia

Professor Louise Kenny

University College Cork, Cork, Ireland



Professor Asma Khalil, MD, MBBCh, MRCOG, MSc(Epi), DFSRH, Dip(GUM)

St George's Hospital, London, United Kingdom

Dr. Hely Katariina Laine

University of Oslo Institute for Clinical Medicine, Oslo, Norway

Professor Terence Lao

The Chinese University of Hong Kong, Hong Kong, Hong Kong

Dr. Titia Lely

Dr. Laura Magee

The University of British Columbia, Vancouver, British Columbia, Canada

Dr. Attila Molvarec

Semmelweis University, Budapest, Hungary

Dr. Jenny Myers

Dr. Rob Powers

University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

Dr. Sarosh Rana

Professor Chris Redman

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Dr. Pierre-Yves Robillard

University Hospital of Réunion South Sites, Saint Pierre, Reunion

Professor Shigeru Saito

University of Toyama, Toyama, Japan

Dr. Sicco Scherjon

University Medical Centre Utrecht, Utrecht, The Netherlands

Dr. Marco Scioscia

Don Calabria Sacred Heart Hospital, Negrar, Italy

Dr. Andrew Shennan

Dr. Daniel Vaiman

Cochin Institute, Paris, France

Dr. Herbert Valensise

University of Rome Tor Vergata, Roma, Italy

Dr. Stefan Velorhen

Dr. Willy Wisser

Erasmus University Rotterdam, Rotterdam, The Netherlands

Dr. Stacy Zamudio

University of Medicine and Dentistry of New Jersey, Department of Orthodontics, Newark, New Jersey, United States of America

All members of the Editorial Board have identified their affiliated institutions or organizations, along with the corresponding country or geographic region. Elsevier remains neutral with regard to any jurisdictional claims.




All content on this site: Copyright © 2023 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.





Contents lists available at ScienceDirect

Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health

journal homepage: www.elsevier.com/locate/preghy

A retrospective cohort study of hypertension, cardiovascular disease, and metabolic syndrome risk in women with history of preterm and term preeclampsia five years after delivery

Aditiawarman^{a,b,*}, Noor Assyifa Zuhijayanti^b, Ernawati Ernawati^{a,b},
Muhammad Ilham Aldika Akbar^{a,c}

^a Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia

^b Department of Obstetrics and Gynecology, Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia

^c Department of Obstetrics and Gynecology, Universitas Airlangga Academic Hospital, Surabaya, East Java, Indonesia

ARTICLE INFO

Keywords:

Preeclampsia
Long-term impact
Maternal health
Cardiovascular disease
Metabolic disease

ABSTRACT

Objectives: To evaluate maternal hypertension, risk of cardiovascular disease (CVD), and metabolic syndrome five years after delivery in preterm preeclampsia (P-PE), term preeclampsia (T-PE), and normal pregnancy.

Study design: This was a retrospective cohort study of women who delivered at Dr. Soetomo Academic Hospital (Indonesia) in 2013 with a diagnosis of PE and were compared with women with normal pregnancies.

Main outcomes measures: Blood pressure, National Cholesterol Education Program Adult Treatment Panel III criteria for metabolic syndrome (NCE-ATP III), and Framingham Risk Score (FRS).

Results: In this study, 92 women participated. They were divided into the P-PE (27), T-PE (35), and control groups (30). Women with a history of PE, P-PE, or T-PE had higher blood pressure five years after delivery than those in the control group ($p < 0.05$). Systolic blood pressure (SBP) >140 mmHg was seen in 66.7% of P-PE and 25.7% of T-PE, while 55.6% of P-PE and 34.3% of T-PE had diastolic blood pressure (DBP) >90 mmHg ($p < 0.05$). Women with P-PE had the highest risk of developing hypertension (Relative risk (RR): 20; 95% Confidence interval [CI]: 2.85–139.92). Women with history of P-PE (RR: 1.85; 95% CI: 0.77–4.41), T-PE (RR: 1.28; 95% CI: 0.51–3.19), and total PE (RR: 1.53; 95% CI: 0.68–3.43) had an increased risk of positive NCEP-ATP III five years after delivery. Women with history of P-PE (RR: 5.17; 95% CI: 0.26–103.22; $p = 0.282$) and T-PE (RR: 6.03; 95% CI: 0.32–112.22; $p = 0.228$) are at a greater risk of having an FRS $>10\%$ compared to the control group ($p = 0.04$).

Conclusions: History of PE, P-PE, and T-PE increased the risk of hypertension and CVD five years after delivery. The results also showed a tendency toward an increased risk of metabolic syndrome in women with a previous history of PE and P-PE.

1. Introduction

Preeclampsia (PE) is a major obstetrics issue, particularly in under-developed nations, where it is a leading cause of maternal mortality (10%–15%) [1]. According to 74 scientific studies on PE across 40 countries, 1.4%–4.6% of pregnancies are affected by pre-eclampsia [2].

PE and eclampsia were the leading causes of maternal death at Dr. Soetomo General Academic Hospital in Surabaya in 2010 [3,4]. In 2014, the incidence of PE at Dr. Soetomo General Academic Hospital in Surabaya, Indonesia increased from 27.88% to 32.48%. A 2016 multicenter retrospective study of seven tertiary care hospitals in Indonesia reported that the prevalence of hypertension during pregnancy was 22.1% in a

Abbreviations: CI, Confidence Interval; CHAMPS, The Cardiovascular Health After Mother Placental Syndromes; CVD, Cardiovascular Disease; DBP, Diastolic Blood Pressure; DM, Diabetes Mellitus; FBG, Fasting Blood Glucose; FRS, Framingham Risk Score; HDL, High-density Lipoprotein; LDL, Low-density Lipoprotein; MAP, Mean Arterial Pressure; NCE-ATP III, National Cholesterol Education Program Adult Treatment Panel III; OR, Odds Ratio; PE, Preeclampsia; P-PE, Preterm Preeclampsia; RR, Relative Risk; SBP, Systolic Blood Pressure; SGA, Small for Gestational Age; TC, Total Cholesterol; TG, Triglyceride; T-PE, Term Preeclampsia.

* Corresponding author at: Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Mayjen Prof. Dr. Moestopo 47, Surabaya, East Java 60131, Indonesia.

E-mail address: aditiawarman@fk.unair.ac.id (Aditiawarman).

<https://doi.org/10.1016/j.preghy.2023.04.003>

Received 30 December 2022; Received in revised form 7 April 2023; Accepted 15 April 2023

2210-7789/© 2023 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

total of 17,771 deliveries. Among those, 54% were classified as having late-onset preeclampsia and 46% as having early onset preeclampsia. Maternal and perinatal mortality rates were 2% and 12%, respectively. Dr. Soetomo Academic Hospital saw a high incidence of severe complicated preeclampsia as it is the only tertiary referral hospital in East Java [5].

PE causes substantial morbidity and mortality in the mother and fetus or infant owing to multisystem organ dysfunction[6,7]. PE is divided into two categories based on delivery timing: preterm PE (P-PE) was diagnosed if PE led to delivery before 37 weeks; term PE (T-PE) was diagnosed if PE led to delivery ≥ 37 weeks[8–10]. P-PE and T-PE are hypothesized to result from distinct etiology [11–13]. P-PE occurs during the first trimester of pregnancy and is associated with immunological and inflammatory responses during implantation. This process involves release of several growth factors and cytokines. P-PE is characterized by shallow trophoblast invasion and suboptimal vascular remodeling, resulting in placental hypoperfusion. This results in the release of reactive chemicals that enter the bloodstream and damage the endothelium, which is essential for maintaining the balance between vasodilation and vasoconstriction via nitric oxide synthesis. In contrast, T-PE is primarily caused by maternal vascular and chronic inflammatory maladaptation, ultimately resulting in preeclampsia[11]. This distinction affects clinical presentation, severity, and prognosis of P-PE compared to those of T-PE. Christensen et al. demonstrated that the gestational age at the onset of preeclampsia is negatively associated with markers of subclinical atherosclerosis, including carotid plaque presence, carotid intima-media thickness, aortic pulse wave velocity, and heart rate augmentation index, 12 years after delivery. After delivery, women with P-PE had worse atherosclerotic characteristics than women with T-PE[12]. In an Australian national cohort study, hypertension in pregnancy, especially early onset hypertension, was associated with a higher risk of cardiovascular disease (CVD) than late-onset hypertension, which was enhanced by smoking[13].

PE is an issue because of its association with mortality and short-term morbidity, and its role in long-term morbidities such as chronic hypertension, CVD, cerebrovascular illness, and metabolic syndrome[14–16]. Indonesia has a much higher incidence of female metabolic syndrome than European countries. Sigit et al. reported that the prevalence of metabolic syndrome was 46% in Indonesian women and 24% in Dutch women[17]. Compared with women without a history of PE in pregnancy, women with a history of PE in pregnancy have a higher incidence of metabolic syndrome. Obesity, hypertension, insulin resistance, high fasting blood sugar levels, dyslipidemia, and microalbuminuria are the risk factors for CVD. PE can increase the likelihood of developing metabolic syndrome, which may be the primary cause of development of CVD. In a meta-analysis encompassing 55,695 patients, PE was found to significantly increase the risk of metabolic syndrome (Crude odds ratios [OR] = 2.93; 95% confidence interval [CI] = 1.92–4.47 and Adjusted OR = 1.62; 95% CI = 1.25–2.08)[18]. PE shares similar risk factors and pathophysiological problems with arterial-coronary illnesses, including insulin resistance. Framingham Risk Score (FRS) can be used to predict the probability of developing CVD 10 years after PE. A previous study found that the risk of developing CVD was 4.52 times higher in women with a history of PE compared with women with no history of PE[19]. Metabolic syndrome refers to a group of disorders that increase the risk of various diseases[20]. Most studies have indicated that women with preeclampsia have an increased risk of developing metabolic syndrome after birthing, indicating its role in the pathophysiology of diseases, ranging from preeclampsia to long-term CVD. Metabolic syndrome was diagnosed using the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III)[21].

To date, no Indonesian studies have linked the onset of PE to the risk of chronic hypertension, CVD, or metabolic syndrome. This study was conducted to determine the risk of maternal hypertension, CVD disorders, and metabolic syndrome five years after delivery in women with severe preeclampsia (P-PE and T-PE) compared with normal pregnancy

using clinical and laboratory measurements, FRS[21], and NCEP-ATP III criteria[22].

2. Methods

This retrospective cohort study was conducted at Dr. Sutomo General Academic Hospital, Surabaya, Indonesia from January 2018 to December 2018 and was approved by the hospital ethics committee. This study consisted of women with or without PE (during pregnancy and delivery) who delivered in the hospital five years prior to 2018 (Jan 2013 to Dec 2013). Purposive sampling was used to select these criteria. Women with a normal pregnancy, no signs or symptoms of PE during pregnancy and delivery, and a term birth in 2013 comprised the control group. The other groups consisted of women with PE during pregnancy who delivered in 2013. The PE groups were separated based on delivery timing into P-PE (delivered at <37 weeks) and T-PE (delivered at ≥ 37 weeks) groups. Patients with obesity, chronic hypertension, congenital cardiac disease, diabetes mellitus, autoimmune disease, or rheumatism before or during pregnancy were excluded.

Primary outcomes were hypertension, metabolic syndrome, and CVD risk. We also measured maternal serum markers of metabolic syndrome: high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), total cholesterol (TC), and fasting blood glucose (FBG) levels. The diagnosis of hypertension during pregnancy, P-PE, and T-PE was based on the International Society for the Study of Hypertension in Pregnancy (ISSHP) definition[23,24]. Hypertension was defined as systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) >90 mmHg, based on the average of at least two measurements[24]. Metabolic syndrome was diagnosed according to the NCEP-ATP III criteria[25]. According to the NCEP-ATP III definition, metabolic syndrome occurs when three or more of the following five conditions are met: waist circumference >35 in, blood pressure >130/85 mmHg, fasting TG levels >150 mg/dL, fasting HDL cholesterol (HDL) levels <50 mg/dL, and FBG level >100 mg/dL[25]. Additionally, we measured the birth weight percentile, percentile <10, and percentile <5 using the INTERGROWTH calculator to evaluate neonatal outcomes[26].

The FRS was used to assess the risk of CVD. Six coronary risk factors, namely, age, sex, TC, HDL, SBP, and smoking behavior, were used to produce the FRS. The calculation thresholds for FRS were: TC <160, 160–199, 200–239, 240–279, and ≥ 280 mg/dL; SBP <120, 120–129, 130–139, 140–159, and ≥ 160 mmHg; HDL <40, 40–49, 50–59, and ≥ 60 mg/dL. Total points were used to determine the 10-year risk in percentage terms (1 point = 6%, 2 points = 8%, 3 points = 10%, 4 points = 12%, 5 points = 16%, 6 points = 20%, 7 points = 25%, and 10 points or more >30%). The percentage of absolute CVD risk over a 10-year period was categorized as low risk (10%), intermediate risk (10%–20%), and high risk (>20%)[27].

Patients were selected from the database of medical records at Dr. Soetomo Academic Hospital between January 2016 and December 2016 based on the inclusion and exclusion criteria. The researchers contacted the participants and informed them about the study. Patients who agreed to participate signed an informed consent form. The researcher then performed a clinical assessment and collected blood samples. Blood pressure was measured using a standardized method: women in a seated position with their feet flat on the floor, correct cuff size, Korotkoff V for DBP, and an automated device[28]. Blood pressure was measured twice in each arm with a 15-minute interval between measurements. Blood pressure was determined by averaging two readings. Subsequently, body weight (kg), height (cm), and waist circumference (cm) were measured. Waist circumference was measured using a flexible measuring tape. The tape measure was wrapped around the broadest section of the abdomen across the belly button and measured while the woman exhaled. Three milliliters of blood were collected to determine the serum levels of blood TG; fasting blood sugar; and total, LDL, and HDL cholesterol (mg/dL). All measurements were performed using automated laboratory procedures.

Statistical analyses were performed using the SPSS 25. Data are initially presented using descriptive statistics, followed by a test of normality distribution. We analyzed the statistical differences in categorical data using the chi-square test (normally distributed data) or Fisher's exact test (abnormally distributed data). For the numerical data, we measured the differences using either the *t*-test or Mann–Whitney *U* test, depending on the normality distribution of the numerical data. The relative risk was measured for categorical data for each parameter.

3. Results

From the evaluated medical records of 452 preeclamptic pregnancies, only 62 patients met the selection criteria, including 27 with P-PE and 35 with T-PE (Fig. 1). Of the 452 patients, 256 were excluded because of chronic hypertension (60), Diabetes Mellitus (DM) (65), obesity (105), heart disease (15), and autoimmune disease (15). Thirty women with normotensive pregnancies who delivered term-delivered infants were included in the control group. The maternal history and background characteristics of the groups are shown in Table 1. Maternal age was higher in the T-PE group than in the P-PE and control groups. The P-PE group had a higher incidence of maternal complications (55.55% vs. 14.28%), cesarean delivery (74.1% vs. 57.1%), and perinatal death (29.6% vs. 8.2%). In addition, the gestational age at delivery was lower in the P-PE group than that in the T-PE and control groups ($p < 0.05$) (Table 1). Table 2 compares the clinical and laboratory examinations of the PE, P-PE, and T-PE groups with those of the control group. Five years after delivery, 66.7%, 27.5%, and 3.3% of women in the P-PE, T-PE, and control groups, respectively, had hypertension.

Both the clinical and laboratory results were significantly different between the PE and control groups (Table 2). Mean SBP and DBP (87.95 ± 16.71 vs 66.53 ± 11.41 mmHg), Mean Arterial Pressure (MAP) (105.9 ± 16.71 vs 66.53 ± 11.41 mmHg), waist circumference (88.74 ± 10.90 vs 83.46 ± 2.09 cm), TC (224.46 ± 101.66 vs 175.47 ± 46.97 mg/dL), LDL (120.74 ± 70.08 vs 83.7 ± 36.29 mg/dL), TG (263.68 ± 230.42 vs 154.43 ± 47.35 mg/dL), and FBG (107.45 ± 64.01 vs 84.3 ± 21.98 mg/dL) of the PE group were significantly higher compared to those of the control group ($p < 0.05$). However, the mean HDL of the PE group was lower compared to the control group (51.61 ± 13.57 vs 60.83 ± 3.42 mg/dl; $p <$

Table 1

Maternal History and Background Characteristics.

	Control (n = 30)	Preterm PE (n = 27)	Term PE (n = 35)	<i>p</i>
Maternal Ages (years old)	33.1±6.05	36.93±6.65	39.31±6.16	0.001^a
Nullipara [n (%)]	19 (63.3)	14 (51.9)	21 (60)	0.666 ^b
BMI (kg/m ²)	25.84±2.64	27.94±2.87	25.48±3.09	0.003^a
SBP during pregnancy (mmHg)	111.67±5.76	145±30.41	131.80±23.74	0.000^a
DBP during pregnancy (mmHg)	70.67±9.07	90±16.41	84±15.75	0.000^a
Complications [n (%)]	0	15 (55.55)	5 (14.28)	0.051 ^b
Acute Kidney Injury [n (%)]	0	2 (7.41)	0	–
HELLP Syndrome [n (%)]	0	1 (3.70)	2 (5.71)	–
Eclampsia [n (%)]	0	2 (7.41)	1 (2.85)	–
Acute Pulmonary Edema [n (%)]	0	0	2 (5.71)	–
Multiple complications [n (%)]	0	4 (14.81)	0	–
GA at delivery (weeks)	38.63±1.40	32.04±2.19	37.77±2.00	0.000^a
Cesarean delivery [n (%)]	10 (33.3)	20 (74.1)	20 (57.1)	0.008^b
Birth weight (g)	2950±366.72	1695±445.97	3002.94±557.31	0.000^a
Birthweight percentile	41.32±21.78	28.51±24.87	55.54±30.15	0.001^a
Birthweight percentile < 10n (%)	0	9 (33.3)	2 (5.7)	0.000^b
Birthweight percentile < 5n (%)	0	4 (14.8)	1 (2.9)	0.033^b
Perinatal death [n (%)]	0	8 (29.6)	3 (8.6)	0.002^b

^a One Way ANOVA.

^b Chi-square test.




Fig. 1. Algorithm Patients Recruitment.

Table 2

Comparison of Clinical and Laboratory Examination of Preterm PE, Term PE, and PE (total) Compared with Control.

	PE (total) (N = 62)	Preterm PE (N = 27)	Term PE (N = 35)	Control (N = 30)	PE (total) vs control	Preterm PE vs Control	Term PE vs Control
SBP (mm Hg)	141.90±24.02	154.96±23.48	131.83±19.34	115.60±14.25	p < 0.01	p < 0.01	p < 0.01
DBP (mm Hg)	87.95±16.71	96.00±16.163	81.7±14.49	66.53±11.41	p < 0.01	p < 0.01	p < 0.01
MAP (mmHg)	105.90±18.21	115.58±16.99	98.42±15.37	82.80±11.65	p < 0.01	p < 0.01	p < 0.01
Waist Circumferential (cm)	88.74±10.90	93.14±11.89	85.34±8.81	83.46±12.09	P = 0.03	p < 0.01	p = 0.76
HDL (mg/dL)	51.61±13.57	51.74±16.58	51.51±10.96	60.83±13.42	p < 0.01	p = 0.03	p = 0.01
LDL (mg/dL)	120.74±70.08	140.70±64.23	105.34±71.39	83.70±36.29	p < 0.01	p < 0.01	p = 0.31
Triglycerides (mg/dL)	263.68±230.42	331.00±281.254	211.74±168.513	154.43±47.354	P = 0.01	p < 0.01	p = 0.43
Total cholesterol level (mg/dL)	224.46±101.66	257.30±104.63	199.17±93.03	175.47±46.97	P = 0.02	p < 0.01	p = 0.50
Fasting Blood sugar (mg/dL)	107.45±64.01	104.81±37.88	109.48±79.01	84.30±21.98	P = 0.01	p = 0.33	p = 0.15

0.05). P-PE had higher levels of SBP (154.96±23.48 vs 115.6±14.25), DBP (96±16.16 vs 66.53±11.41), MAP (115.58±16.99 vs 82.8±11.65), LDL (140.7±64.23 vs 83.7±36.29), TG (331±281.254 vs 154.43±47.35), and TC (257.3±104.63 vs 175.47±46.97), a larger waist circumference (93.14±11.89 vs 83.46±12.09), and lower HDL levels (51.74±16.58 vs 60.83±13.42) compared to the control group ($p < 0.05$). SBP (131.83±19.34 vs 115.6±14.25), DBP (81.7±14.49 vs 66.53±11.41), MAP (98.42±15.37 vs 82.80±11.65), and HDL levels (51.51±10.96 vs 60.83±13.42) differ significantly between the T-PE group and the control group. P-PE was strongly associated with increased SBP, DBP, MAP, LDL, TG, and TC levels and a larger waist circumference compared with T-PE ($p < 0.05$) (Table 2).

Table 3 shows the NCEP-ATP III classification in all groups at five years after delivery. Positive NCEP-ATP III criteria were found in 37%, 25.7 %, and 20% of the P-PE, T-PE, and control groups, respectively. Women with history of P-PE (Relative Risk (RR): 1.85; 95% CI: 0.77–4.41), T-PE (RR: 1.28; 95% CI: 0.51–3.19), and total PE (RR: 1.53; 95% CI: 0.68–3.43) increase the risk of positive NECP-ATP III five years after delivery (Table 3). FRS analysis showed that most participants were in the low-risk classification: control group (100%), P-PE (92.6%), and T-PE (91.4%) (Table 4). The P-PE group (7.4%) was classified as having a high-risk FRS, while the T-PE group (8.6%) had an intermediate-risk FRS. Our findings revealed that women with P-PE or T-PE are at a greater risk of having an intermediate- or high-risk FRS (>10%) than the control group ($p = 0.04$) (Table 4). However, there was no significant difference in the FRS between total PE and control group ($p = 0.278$) (Table 4). We also measured the relative risk of FRS >10% (intermediate-high risk) in P-PE vs control (RR: 5.17; 95% CI: 0.26–103.22; $p = 0.282$), T-PE vs control (RR: 6.03; 95% CI: 0.32–112.22; $p = 0.228$), and total PE vs control (RR: 5.41; 95% CI: 0.31–94.79; $p = 0.25$).

Additionally, outcomes between total PE and control groups were compared. The incidence of abnormal SBP (43.5% vs. 3.3%), DBP (43.5% vs. 3.3%), and LDL >100 mg/dL (53.2% vs. 26.7%) was substantially higher among women with a history of PE ($p < 0.05$) than in women without a history of PE (Table 5). Excessive waist circumference, HDL, TG, and FBG levels did not differ significantly between the groups ($p > 0.05$) (Table 5). PE, P-PE, and T-PE increased the risk of high blood pressure, waist circumference, and metabolic syndrome serum markers

Table 3

NCEP-ATP III Among Women Five Years After Delivery.

	Control	Preterm PE	Term PE	<i>p</i>
Positive	6 (20%)	10 (37%)	9 (25.7%)	0.342 ^a
Negative	24 (80%)	17 (63%)	26 (74.3%)	
	Control	Total PE		<i>p</i>
Positive	6 (20%)	19 (30%)		0.282 ^a
Negative	24 (80%)	43 (70%)		

^a Chi-square test.**Table 4**

Framingham Risk Score Classification in Women Five Years After Delivery.

	Control (n = 30)	Preterm PE (n = 27)	Term PE (n = 35)	<i>p</i>
Low Risk (<10%)	30 (100%)	25 (92.6%)	32 (91.4%)	0.04^a
Intermediate Risk (10–20%)	0	0	3 (8.6%)	
High Risk (>20%)	0	2 (7.4%)	0	
	Control (n = 30)	Total PE (n = 62)		<i>p</i>
Low Risk (<10%)	30 (100%)	57 (91.9%)		0.278^a
Intermediate Risk (10–20%)	0	3 (4.8%)		
High Risk (>20%)	0	2 (3.3%)		

^a Chi-square test.**Table 5**

Blood Pressure and Metabolic Syndrome Markers in Control vs PE Group.

	Control (n = 30)	PE (n = 62)	P value	RR (95% CI)
Systolic blood pressure > 140 mmHg	1 (3.30%)	27 (43.5%)	<	13.08 (1.86–91.62)
Diastolic Blood Pressure >90 mm Hg	1 (3.30%)	27 (43.5%)	<	13.06 (1.86–91.82)
Waist Circumference >88 cm	10 (33.3%)	28 (45.2%)	0.28 ^a	1.35 (0.76–2.40)
LDL >100 mg/dL	8 (26.7%)	33 (53.2%)	0.01^a	1.99 (1.05–3.78)
HDL <50 mg/dL	7 (23.3%)	28 (45.2%)	0.06 ^a	1.93 (0.95–3.91)
Triglycerides >150 mg/dL	16 (53.3%)	40 (64.5%)	0.30 ^a	1.21 (0.82–1.77)
Fasting blood sugar >125 mg/dL	2 (6.7%)	13 (21.0%)	0.08 ^a	3.14 (075–13.05)

^a Chi-square test.

five years after disease development (Table 6). The P-PE group has the highest risk of developing high blood pressure, with a risk for SBP >140 mmHg (RR: 20.00; 95% CI: 2.85–139.92) and DBP >90 mmHg (RR: 16.67; 95% CI: 2.35–117.92). P-PE also has a higher risk for LDL (>100 mg/dL) compared to the control group (RR: 2.78; 95% CI: 1.47–5.24). Meanwhile women with T-PE were at a higher risk to develop high SBP (RR: 7.71; 95% CI: 1.03–57.43) and DBP (RR: 10.26; 95% CI: 1.41–74.56) (Table 6).

4. Discussion

This is the first study from Indonesia to investigate the risk of CVD and metabolic syndrome following preeclamptic pregnancy based on delivery timing (P-PE or T-PE). After postpartum haemorrhage, PE is the second leading cause of maternal death in Indonesia [29]. In Indonesia, the maternal mortality rate is 305 per 100,000 live births

Table 6

Risk of Abnormal Systolic and Diastolic Blood Pressure, Waist Circumference, Triglyceride, LDL, HDL, and Fasting Blood Glucose in the Preterm PE, Term PE, and Control Groups.

	SBP <140 mmHg	SBP >140 mmHg	p	RR (95% CI)
Control subject	29/30 (96.70%)	1/30(3.30%)		1
Preterm PE	9/27 (33.3%)	18/27 (66.7%)	<0.01	20.00 (2.85–139.92)
Term PE	26/25(74.3%)	9/25(25.7%)	0.01	7.71 (1.03–57.43)
Control subject	DBP <90 mmHg 29/30 (96.70%)	DBP >90 mmHg 1/30(3.30%)		1
Preterm PE	12/27(44.4%)	15/27 (55.6%)	<0.01	16.67 (2.35–117.88)
Term PE	23/35 (67.7%)	12/35 (34.3%)	<0.01	10.26 (1.41–74.56)
Control subject	Waist circumferential <88 cm 20/30(66.7%)	Waist circumferential >88 cm 10/30 (33.3%)		1
Preterm PE	12/27 (44.4%)	15/27 (55.6%)	0.09	1.66 (0.90–3.06)
Term PE	22/35 (44.4%)	13/35 (55.6%)	0.75	1.11 (0.57–2.16)
Control subject	LDL <100 mg/dL 22/30 (73.3%)	LDL >100 mg/dL 8/30 (26.7%)		1
Preterm PE	7/27 (25.9%)	20/27 (74.1%)	<0.01	2.78 (1.47–5.24)
Term PE	22/35 (62.8%)	13/35 (37.2%)	0.37	1.39 (0.67–2.9)
Control subject	HDL >50 mg/dL 23/30(76.7%)	HDL <50 mg/dL 7/30 (23.3%)		1
Preterm PE	15/27 (55.6%)	12/27 (44.4%)	0.09	0.72 (0.49–1.07)
Term PE	19/35 (54.3%)	16/35 (45.7%)	0.05	0.70 (0.49–1.01)
Control subject	Triglycerides <150 mg/dL 14/30 (46.7 %)	Triglycerides >150 mg/dL 16/30 (53.3%)		1
Preterm PE	7/27 (25.9%)	20/27 (74.1%)	0.10	1.38 (0.92–2.07)
Term PE	15/35 (42.9%)	20/35 (57.1%)	0.75	1.07 (0.68–1.66)
Control subject	Fasting blood sugar <125 mg/dL 28/30 (93.3 %)	Fasting blood sugar >125 mg/dL 2/30 (6.7 %)		1
Preterm PE	20/27 (74.1 %)	7/27 (25.9 %)	0.07	3.88 (0.88–17.13)
Term PE	29/35 (82.9 %)	6/35 (17.1 %)	0.22	2.57 (0.56–11.80)

[5,29]. We discovered that after five years women with a history of PE had higher blood pressure than women with no history of PE. A history of PE increased the risk of SBP >140/90 mmHg (RR: 13.08) and DBP >90 mmHg (RR: 13.06) compared to non-PE pregnancies. Moreover, P-PE was associated with a greater risk of developing hypertension (higher SBP, DBP, and MAP) five years after occurrence than T-PE. The risk of developing an SBP \geq 140 mmHg (RR: 20 vs. 7.71) and a DBP \geq 90 mmHg (RR: 16.67 vs 10.26) was higher in the P-PE group than in the T-PE

group. Numerous studies reveal that PE increases the chance of developing CVD, metabolic syndrome, and hypertension by more than threefold (RR: 3.7; 95% CI: 2.50–5.05) after 14.1 years [30–33]. In one study, 50% of the women with a history of PE had chronic hypertension, and the highest blood pressure levels were reported in patients with early onset PE[34,35]. Increases in blood pressure tend to be related to alterations in lipid profile and metabolic syndrome characteristics, which are significantly distinct from those in PE-free women. The Cardiovascular Health After Mother Placental Syndromes (CHAMPS) Study found that women with PE had a 12-fold higher risk of developing CVD and metabolic syndrome than women without PE[31]. Lipid profile, waist circumference, and blood sugar levels all affect the risk of developing atherosclerosis in the blood vessels. Theoretically, atherosclerosis begins when LDL interacts with macrophage chemoattractant proteins to activate them, thereby promoting monocyte development. This reaction results in endothelial damage and formation of atherosclerotic plaques. As a result, an imbalance in nitric oxide levels increases blood pressure and mean arterial pressure[32,33]. This study implies that severe PE is associated with an increase in cardio-metabolic risk at 5 years post-delivery.

Based on marker abnormalities (waist circumference, LDL, HDL, TG, TC, and FBG), this study found that women with a history of PE and P-PE had a greater chance of developing metabolic syndrome than women without a history of PE. Compared to women with normal pregnancies, those with a history of PE had a higher prevalence of LDL levels >100 mg/dL. Metabolic syndrome, characterized by alterations in lipid profile, FBG level, and waist circumference, increases the risk of type II diabetes, coronary heart disease (CHD), and stroke[32]. According to two meta-analyses, women with a history of PE had a three-fold increased risk of developing hypertension and a two-fold increased risk of developing stroke and ischemic heart disease later in life[35]. Contrary to previous findings, none of the patients in this study were diagnosed with type II diabetes, CHD, or stroke five years after PE. This is likely due to the gradual progression from metabolic changes to disease occurrence. In addition, our results indicate an upward tendency in metabolic syndrome markers, which may eventually manifest as the previously mentioned diseases later in life[33,35].

Similar to previous studies [36–42], the sample data were divided into P-PE and T-PE to evaluate whether PE type influenced chronic hypertension, metabolic syndrome, and CVD. This study demonstrated that P-PE had a greater impact on metabolic syndrome markers (lipid profiles and waist circumference) than T-PE. The P-PE group had a higher average abnormal waist circumference and LDL, HDL, TG, TC, and FBG levels than the control group. In contrast, women with T-PE only had abnormal HDL levels compared to women without PE. In a study of 718 women with a history of preeclampsia, Veerbeek et al. found that lipid profiles and fasting blood sugar levels were significantly different between early onset PE, late-onset PE, and gestational hypertension. Early onset PE had the worst profile compared to the other two conditions[43]. In a cohort analysis of 1102 women with a history of PE, the incidence of postpartum metabolic syndrome was more strongly related to P-PE combined with small for gestational age (SGA) than to T-PE or P-PE without SGA. Both the timing of PE and fetal growth restriction influence the likelihood of developing metabolic syndrome following a preeclamptic pregnancy[10,44].

This study revealed that women with a history of PE, either P-PE or T-PE, had a substantially increased risk of CVD (based on FRS). In accordance with similar findings, our results demonstrated the significance of PE in the development of heart disease. In a meta-analysis involving >6 million women and 258 thousand women with a history of PE, PE was associated with a four-fold increase in the future incidence of heart failure and a two-fold increase in the risk of coronary heart disease, stroke, and CVD-related death[36]. In addition, we discovered that patients with P-PE had higher FRS than those with T-PE. This is consistent with the findings of a meta-analysis that included >3.5 million women, which demonstrated that CVD risk is dependent on

certain pregnancy factors, such as the timing of PE. Women with P-PE have a noticeably increased risk of CVD compared with women with T-PE (RR: 7.71, 95% CI: 4.40–13.52 vs RR: 2.16, 95% CI: 1.86–2.52)[37].

In addition, although not statistically significant, women with a history of PE tended to have a higher risk of metabolic syndrome based on NCEP-ATP III criteria. Both FRS and metabolic syndrome can predict the risk of CVD and diabetes, with FRS being more predictive of CVD [44]. Our study found that women with a history of PE, P-PE, or T-PE had significantly lower HDLC levels. HDL is a lipoprotein marker that has the greatest impact on the value of cardiovascular events relative to other lipoprotein variables. Low HDL levels increase the incidence of cardiovascular events by 1.34 times (95% CI: 1.24–1.44)[45].

The incidence of hypertension, metabolic syndrome, and cardiovascular risk later in life was higher among women with P-PE than among those with T-PE[46]. However, the exact explanation for these findings remains controversial. Some researchers have argued that PE can cause sustained damage to the vascular endothelium after delivery [47]. The endothelial damage sustained in P-PE is likely to be more severe and persistent than that in T-PE. Additionally, P-PE and T-PE exhibited distinct vascular adaptations. Patients with P-PE had a higher total vascular resistance than those with T-PE[48]. Increased vascular resistance leads to vascular dysfunction and ultimately to hypertension, which increases the risk of CVD[43].

In this study, the majority of women with a history of PE were still of reproductive age five years after delivery, necessitating health treatment and monitoring. Interventions are advantageous for women with a history of PE[49]. Our findings can be used to prevent CVDs and other metabolic disorders in cases of P-PE. Short- and long-term preventive interventions must include routine screening for CVD risk factors and other metabolic syndrome, as well as ongoing maintenance of a healthy lifestyle[43,46,50]. The American College of Obstetricians and Gynecologists recommends that all women affected by hypertension during pregnancy have initial contact with an obstetric care provider within three weeks postpartum, followed by a comprehensive postpartum visit within 12 weeks postpartum and annual cardiovascular follow-up thereafter[51]. The American Heart Association advises cardiovascular follow-up after HDP, but does not specify a period[52]. For all women with HDP, Kavia et al. proposed a regimen based on follow-up during the first two weeks postpartum and 6–12 weeks postpartum, with specialty follow-up for persistent hypertension, proteinuria, or hyperglycemia at delivery discharge, and annually thereafter[53]. Modifying lifestyle habits is essential to lower the long-term risk of CVD in women with a history of PE. FIGO's postpartum guidelines for women with pregnancy-related cardiovascular risk markers include breastfeeding and lifestyle changes such as a healthy diet and adequate physical activity[54,55].

5. Conclusion

This study revealed that women with a history of PE, P-PE, or T-PE were more likely to develop hypertension and CVD five years after childbirth. Although this study did not identify individuals with metabolic syndrome (such as diabetes), abnormal biomarker results implied that women with a history of PE had an increased risk of developing metabolic syndrome later in life. The long-term risk of hypertension, CVD, and metabolic syndrome is greatest in P-PE. To reduce these risks, it is essential to regularly examine maternal health and promote healthy lifestyles in women with a history of PE.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The author is grateful to the Department Obstetrics & Gynecology, Faculty of Medicine Universitas Airlangga, who has supported this study.

References

- [1] L. Duley, The global impact of pre-eclampsia and eclampsia, *Semin Perinatol.* 33 (3) (2009) 130–137.
- [2] E. Abalos, C. Cuesta, A.L. Grosso, D. Chou, L. Say, Global and regional estimates of preeclampsia and eclampsia: a systematic review, *Eur J Obstet Gynecol Reprod Biol.* 170 (1) (2013) 1–7.
- [3] Bes B. Analisis Faktor Penyebab Kejadian 'Preeklampsia' Ibu Hamil untuk Turunkan AKI [Internet]. Unair News. 2017 [cited 2021 Aug 5]. Available from: <http://news.unair.ac.id/2017/07/31/analisis-faktor-penyebab-kejadian-preeklampsia-ibu-hamil-untuk-turunkan-aki>.
- [4] A. Akbar, B. Wicaksono, E.G. Dachlan, Os018., Maternal mortality and its mainly possible causepre-eclampsia/eclampsia in developing country (Surabaya-Indonesia as themodel). *Pregnancy Hypertension: An International Journal of Women's Cardiovascular, Health.* 2(3):184 (2012).
- [5] M.I. Aldika Akbar, M.A. Bachnas, J.C. Mose, E.G. Dachlan, E. Ernawati, G. A. Dekker, et al., 28. The massive problem of preeclampsia in Indonesia: In need of a redesigned national health care system, *Pregnancy Hypertens.* 1 (13) (2018) S16.
- [6] C.F. Pragitar, R. Etika, L. Herawati, A. Aditiawarman, Risks of preterm birth and low Apgar score among preeclamptic women, *Jurnal Kedokteran dan Kesehatan Indonesia.* 11 (1) (2020) 6–17.
- [7] K. Tsabitah, B. Wicaksono, S. Handayani, Severe preeclampsia leads to higher prevalence of mortality and morbidity affecting maternal outcomes in single tertiary hospital, *Majalah Obstetri & Ginekologi.* 28 (3) (2020) 99.
- [8] Y.T. Chen, T.Y. Lin, P.J. Cheng, K.S. Chan, H.Y. Huang, S.W. Shaw, Taiwanese new direction in prediction of early pregnancy preeclampsia, *Taiwan J Obstet Gynecol.* 60 (1) (2021) 66–69.
- [9] M. Ilham, A. Akbar, G. Dachlan, Comparison between Early-onset and Late-onset Preeclampsia by Echocardiographic Examination of Cardiac Output, Total Vascular Peripheral Resistance, and Doppler Velocimetry Examination of Uterine Artery Resistance Index, *Majalah Obstetri & Ginekologi.* 19 (2) (2011) 63–68.
- [10] D. Raymond, E. Peterson, A critical review of early-onset and late-onset preeclampsia, *Obstet Gynecol Surv.* 66 (8) (2011 Aug) 497–506.
- [11] I. Stergiotou, F. Crispi, B. Valenzuela-Alcaraz, B. Bijlens, E. Gratacos, Patterns of maternal vascular remodeling and responsiveness in early- versus late-onset preeclampsia, *Am J Obstet Gynecol.* 209 (6) (2013) 558.e1–558.e14.
- [12] Christensen M, Kronborg CS, Carlsen RK, Eldrup N, Knudsen UB. Early gestational age at preeclampsia onset is associated with subclinical atherosclerosis 12 years after delivery. *Acta Obstet Gynecol Scand* [Internet]. 2017 Sep 1 [cited 2023 Mar 8];96(9):1084–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/28542803>.
- [13] Arnott C, Nelson M, Alfaro Ramirez M, Hyett J, Gale M, Henry A, et al. Maternal cardiovascular risk after hypertensive disorder of pregnancy. *Heart* [Internet]. 2020 Dec 1 [cited 2023 Mar 8]. 106(24). 1927–33. Available from: <https://pubmed.ncbi.nlm.nih.gov/32404402>.
- [14] Y.L. Kuo, T.F. Chan, C.Y. Wu, C.R. Ker, H.P. Tu, Preeclampsia-eclampsia and future cardiovascular risk among women in Taiwan, *Taiwan J Obstet Gynecol.* 57 (3) (2018) 364–369.
- [15] L.M. Amaral, M.W. Cunningham Jr, D.C. Cornelius, B. LaMarca, Preeclampsia: long-term consequences for vascular health, *Vasc Health Risk Manag.* 15 (11) (2015) 403–415.
- [16] M.C. Brown, K.E. Best, M.S. Pearce, J. Waugh, S.C. Robson, R. Bell, Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis, *Eur J Epidemiol.* 28 (1) (2013) 1–19.
- [17] Sigit FS, Tahapary DL, Trompet S, Sartono E, Willems Van Dijk K, Rosendaal FR, et al. The prevalence of metabolic syndrome and its association with body fat distribution in middle-aged individuals from Indonesia and the Netherlands: A cross-sectional analysis of two population-based studies. *Diabetol Metab Syndr* [Internet]. 2020 Jan 7 [cited 2023 Mar 9];12(1):1–11. Available from: <https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0503-1>.
- [18] Poorolajal J, Jenabi E. The association between body mass index and preeclampsia: a meta-analysis. <https://doi.org/10.3109/1476705820161140738> [Internet]. 2016 Nov 16 [cited 2023 Mar 8];29(22):3670–6. Available from: <https://www.tandfonline.com/doi/abs/10.3109/14767058.2016.1140738>.
- [19] P. Bhasin, S. Kapoor, Pregnancy complications and calculated cardiovascular risk in urban women: do we envisage an association? *J Urban Health.* 91 (1) (2014) 162–175.
- [20] Ju DH, Lee H, Ha SJ. The presence of hypertension during pregnancy determines the future risk of metabolic syndrome: An observational study. *Medicine* [Internet]. 2022 Oct 21 [cited 2022 Dec 29];101(42):E31272. Available from: <https://pubmed.ncbi.nlm.nih.gov/36281202>.
- [21] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA: The Journal of the American Medical Association* [Internet]. 2001 May 16 [cited 2022 Dec 12];285(19):2486–97. Available from: <http://jama.ama-assn.org/cgi/doi/10.1001/jama.285.19.2486>.

- [22] Expert Panel on Detection, Evaluation and T of HBC in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001 May. 285 (19). 2486–97.
- [23] Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Pregnancy Hypertens*. 2013 Jan. 3 (1). 44–7.
- [24] L.A. Magee, M.A. Brown, D.R. Hall, S. Gupte, A. Hennessy, S.A. Karumanchi, et al., The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice, *Pregnancy Hypertens*. 1 (27) (2022) 148–169.
- [25] Huang PL. A comprehensive definition for metabolic syndrome. *DMM Disease Models and Mechanisms* [Internet]. 2009 May [cited 2022 Dec 30];2(5–6):231–7. Available from: <https://pmc/articles/PMC2675814>.
- [26] Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. *Lancet* [Internet]. 2014 [cited 2023 Mar 9];384 (9946):857–68. Available from: <https://pubmed.ncbi.nlm.nih.gov/25209487/>.
- [27] 27. Jahangiry L, Farhangi MA, Rezaei F. Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome. *J Health Popul Nutr* [Internet]. 2017 Nov 13 [cited 2022 Dec 29]. 36 (1). 1–6. Available from: <https://jhpn.biomedcentral.com/articles/10.1186/s41043-017-0114-0>.
- [28] L.C. Poon, A. Shennan, J.A. Hyett, A. Kapur, E. Hadar, H. Divakar, et al., The International Federation of Gynecology and Obstetrics (FIGO) initiative on preeclampsia: A pragmatic guide for first-trimester screening and prevention, *International Journal of Gynecology & Obstetrics*. 145 (S1) (2019) 1–33.
- [29] Ahmed S, Fullerton J. Challenges of reducing maternal and neonatal mortality in Indonesia : Ways forward. 2019. 144. 1–3.
- [30] H. Fitriani, R.A. Setya, M. Keni, Risk Factors Of Preeclampsia Among Pregnant Women In Indonesia, *KnE Life Sciences*. 15 (2021) 836–841.
- [31] J.G. Ray, M.J. Vermeulen, M.J. Schull, D.A. Redelmeier, Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. *Lancet*. 366 (9499) (2005) 1797–1803.
- [32] V. Blaton, How is the Metabolic Syndrome Related to the Dyslipidemia? *EJIFCC*. 18 (1) (2007) 15–22.
- [33] R.O. Halperin, H.D. Sesso, J. Ma, J.E. Buring, M.J. Stampfer, J.M. Gaziano, Dyslipidemia and the risk of incident hypertension in men, *Hypertension*. 47 (1) (2006) 45–50.
- [34] Y.S. Lin, C.H. Tang, C.Y.C. Yang, L.S. Wu, S.T. Hung, H.L. Hwa, et al., Effect of preeclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan, *Am J Cardiol*. 107 (2) (2011) 325–330.
- [35] L. Bellamy, J.P. Casas, A.D. Hingorani, D.J. Williams, Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis, *BMJ*. 335 (7627) (2007) 974.
- [36] Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health. *Circ Cardiovasc Qual Outcomes* [Internet]. 2017 Feb 1 [cited 2022 Dec 30];10(2). Available from: <http://circoutcomes.ahajournals.org/lookup/suppl/doi:10.1161/CIRCOUTCOMES.116.003497/-/DC1>.
- [37] Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ* [Internet]. 2007 Nov 8 [cited 2022 Dec 30];335(7627):974. Available from: <https://www.bmj.com/content/335/7627/974>.
- [38] Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic Syndrome vs Framingham Risk Score for Prediction of Coronary Heart Disease, Stroke, and Type 2 Diabetes Mellitus. *Arch Intern Med* [Internet]. 2005 Dec 12 [cited 2021 Nov 1]; 165(22):2644. Available from: <http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.165.22.2644>.
- [39] Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. *Circ Cardiovasc Qual Outcomes* [Internet]. 2011 May [cited 2021 Nov 1];4(3): 337–45. Available from: <https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.110.959247>.
- [40] M.I. Akbar, H. Kinanti, E.E. Ernawati, P. Lestari, Maternal and Perinatal Outcomes of Early-onset and Late-onset Preeclampsia at a Tertiary Center Hospital, *Journal of South Asian Federation of Obstetrics and Gynaecology*. 13 (5) (2021) 338–342.
- [41] Staff AC, Redman CWG. The Differences Between Early- and Late-Onset Preeclampsia. In: *Preeclampsia* [Internet]. 2018. p. 157–72. Available from: http://link.springer.com/10.1007/978-981-10-5891-2_10.
- [42] Redman CW. Early and late onset preeclampsia: Two sides of the same coin. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health* [Internet]. 2017;7(2017):58. Available from: <https://doi.org/10.1016/j.preghy.2016.10.011>.
- [43] J.H.W. Veerbeek, W. Hermes, A.Y. Breimer, B.B. van Rijn, S.V. Koenen, B.W. Mol, et al., Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension, *Hypertension*. 65 (3) (2015) 600–606.
- [44] S.G. Wannamethee, A.G. Shaper, L. Lennon, R.W. Morris, Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus, *Arch Intern Med*. 165 (22) (2005) 2644–2650.
- [45] A.D. Sniderman, K. Williams, J.H. Contois, H.M. Monroe, M.J. McQueen, J. de Graaf, et al., A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk, *Circ Cardiovasc Qual Outcomes*. 4 (3) (2011) 337–345.
- [46] J.H.T. Ernawati, M.I.A. Akbar, R.A. Aryananda, M.P. Wardhana, K.E. Gumilar, et al., Maternal Cardiovascular Risk in Early And Late Onset Of Preeclampsia Patients Five Years After Labor: A Comparative Study, *Biochem Cell Arch*. 19 (Supplement 2) (2019) 4721–4728.
- [47] S. Rana, E. Lemoine, J.P. Granger, S.A. Karumanchi, Preeclampsia, *Circ Res*. 124 (7) (2019 Mar 29) 1094–1112.
- [48] H. Valensise, B. Vasapollo, G. Gagliardi, G.P. Novelli, Early and Late preeclampsia: Two different maternal hemodynamic states in the latent phase of the disease, *Hypertension*. 52 (5) (2008 Nov) 873–880.
- [49] Lui NA, Jeyaram G, Henry A. Postpartum Interventions to Reduce Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: A Systematic Review. Vol. 6, *Frontiers in cardiovascular medicine*. 2019. 160.
- [50] A. Bokslag, P.W. Teunissen, C. Franssen, K.F. Van, O. Kamp, W. Ganzevoort, et al., Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life, *The American Journal of Obstetrics & Gynecology*. 216 (5) (2017) 523.e1–523.e7.
- [51] Stuebe A, Auguste T, Gulati M. ACOG Committee Opinion No. 736: Optimizing Postpartum Care. *Obstetrics and gynecology* [Internet]. 2018 May 1 [cited 2023 Mar 10];131(5):E140–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/29683911>.
- [52] Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American heart association. *Circulation* [Internet]. 2011 Mar 22 [cited 2023 Mar 10];123(11):1243–62. Available from: <https://pubmed.ncbi.nlm.nih.gov/21325087>.
- [53] Khosla K, Heimberger S, Nieman KM, Tung A, Shahul S, Staff AC, et al. Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: Recent Advances in Hypertension. *Hypertension* [Internet]. 2021 Oct 1 [cited 2023 Mar 10];78(4):927–35. Available from: <https://www.ahajournals.org/doi/suppl/10.1161/HYPERTENSIONAHA.121.16506>.
- [54] L.C. Poon, L. Nguyen-Hoang, G.N. Smith, L. Bergman, P. O'Brien, M. Hod, et al., Hypertensive disorders of pregnancy and long-term cardiovascular health: FIGO Best Practice Advice, *International Journal of Gynecology and Obstetrics*. 160 (S1) (2023 Jan 1) 22–34.
- [55] Orchard TJ, Temprosa M, Barrett-Connor E, Fowler SE, Goldberg RB, Mather KJ, et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. *Diabet Med* [Internet]. 2013 Jan [cited 2023 Mar 10];30(1):46–Available from: <https://pubmed.ncbi.nlm.nih.gov/22812594>.